Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors | bioRxiv
IJMS | Free Full-Text | The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer
IJMS | Free Full-Text | The Importance of the Immune System and Molecular Cell Signaling Pathways in the Pathogenesis and Progression of Lung Cancer
Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation | Oncogene
Clinical Implication of MicroRNA for Lung Cancer | Cancer Biotherapy and Radiopharmaceuticals
Proteomic and Phosphoproteomic Analyses Reveal the Oncogenic Role of PTK7-NDRG1 Axis in Non-small-cell Lung Cancer Cell Resistance to AZD9291 | ACS Chemical Biology
Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations | medRxiv
Lung Cancer - Oncologic Disorders - Pharmacotherapy A Pathophysiologic Approach, 9th Ed.
SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer | Nature Communications
EGFL7 drives the evolution of resistance to EGFR inhibitors in lung cancer by activating NOTCH signaling | Cell Death & Disease
Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives | Cell Physiol Biochem
Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties
Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations | medRxiv
Novel serum biomarkers for lung cancer early diagnosis and clinical outcome
PDF) Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis
Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer | SpringerLink
PTEN/MMAC1 mutations found in lung cancers | Download Table
IKKα Promotes the Progression and Metastasis of Non-Small Cell Lung Cancer Independently of its Subcellular Localization - ScienceDirect
![PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0cf466fd259f6bee54109793ae154a69035d609c/7-Table4-1.png "PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar")
PDF] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations | Semantic Scholar
pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma | Communications Biology
Frontiers | mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis - Liu - 2020 - Cancer Communications - Wiley Online Library
Frontiers | Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
Lung Cancer | Basicmedical Key
Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer | BMC Cancer | Full Text
Prognosis of Different Types of Non-Small Cell Lung Cancer Progression: Current State and Perspectives | Cell Physiol Biochem
